IBRX (ImmunityBio) Loans Receivable: $0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IBRX ImmunityBio Inc IBRX
60 GF Score
Price $8.40
GF Value $22.42
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ImmunityBio Loans Receivable?

ImmunityBio IBRX +1.82% 60 Loans Receivable is $0.0 Mil as of Jun. 2026. GuruFocus rates IBRX with a GF Score™ of 60/100 and a GF Value™ of $22.42 (Possible Value Trap). The stock has 5 warning signs investors should review.

ImmunityBio's Loans Receivable for the quarter that ended in Jun. 2026 was $0.0 Mil.

ImmunityBio Loans Receivable Historical Data

* Premium members only.

The historical data trend for ImmunityBio's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmunityBio Loans Receivable Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ImmunityBio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
IBRX
60GF Score
ImmunityBio Inc IBRX
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmunityBio Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.0 Mil mean?
ImmunityBio (IBRX) has a Loans Receivable of $0.0 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on ImmunityBio and its competitors.
Is ImmunityBio's Loans Receivable too high?
ImmunityBio's current Loans Receivable is $0.0 Mil. Overall, ImmunityBio has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ImmunityBio's Loans Receivable compare to RYTM and PCVX?
ImmunityBio's Loans Receivable of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on ImmunityBio and its competitors. ImmunityBio's current Loans Receivable is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmunityBio stock overvalued right now?
Based on GuruFocus' analysis, ImmunityBio (IBRX) is currently considered Possible Value Trap. The stock's GF Value™ is $22.42, compared to a current price of $8.40 — trading 62.6% below its estimated fair value. The current Loans Receivable is $0.0 Mil. ImmunityBio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For ImmunityBio (IBRX), the current Loans Receivable is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmunityBio (IBRX) Overvalued in 2026?

Based on GuruFocus' analysis, ImmunityBio stock appears to be undervalued. The current stock price of $8.40 is trading 62.6% below its estimated GF Value™ of $22.42. GuruFocus considers ImmunityBio to be Possible Value Trap.

Key valuation signals for IBRX:

  • Loans Receivable: $0.0 Mil
  • GF Value™: $22.42 vs. price of $8.40 (62.6% below fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the IBRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmunityBio Business Description

Other Exchanges 26CA:Germany
Address 3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
60GF Score

Get the complete analysis for IBRX

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.40
Price
$22.42
GF Value